

REMARKS

Claims 1, 2 and 4-9 are pending. Claims 4 and 5 have been withdrawn from consideration. By this Amendment, Applicants amended Claims 1, 2, 6 and 8-9. No new matter has been added.

In the Office Action mailed May 4, 2009, claim 1 was objected to because of the second recitation of the word “form.” As amended, claim 1 does not contain the extra recitation of the word “form.” In light of the amendment to the claim, withdrawal of this objection is respectfully requested.

Claims 1, 2 and 6-9 are rejected under 35 U.S.C. § 112, second paragraph, as indefinite with respect to the recitation of the article “a” with the recitation of “prostate specific antigen.” As suggested by the Examiner, Applicants have removed the article “a” preceding the recitation of “prostate-specific antigen.” In light of the amendment to the claim, withdrawal of this rejection is respectfully requested.

Claims 1, 2 and 6-9 are rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement for encompassing both anti-PSA antibodies and PSA itself. The Examiner contends that the limitation comprising both anti-PSA antibodies and PSA itself is not supported by the specification. Applicants clarified the claims to encompass only anti-PSA antibodies which limitation is supported by the specification and original claims as filed. In light of the amendment, withdrawal of this rejection is respectfully requested.

Claims 1, 2 and 6-9 are further rejected under 35 U.S.C. § 112, first paragraph, as not enabled by the specification. The Examiner states that the specification “while being enabling for a medicament for treating benign prostatic hyperplasia or prostatitis, does not reasonably provide enablement for a medicament for treating a generically recited ‘disease of the prostate.’” As amended claims 1, 2 and 6-9 are clearly directed to a medicament for treating benign prostatic hyperplasia or prostatitis. As further pointed

out by the Examiner on page 5 of the Office Action, Applicants have provided evidence that the claimed medicament is effective in treating benign prostatic hyperplasia or prostatitis. In light of the amendment to the claim, withdrawal of this rejection is respectfully requested.

The applicants respectfully request reconsideration and allowance in view of the above remarks and amendments. The Examiner is authorized to deduct additional fees believed due from our Deposit Account No. 50-4711.

KAPLAN GILMAN & PERGAMENT LLP
1480 Route 9 North, Suite 204
Woodbridge, New Jersey 07095
Telephone (732) 636-4500

Dated: May 29, 2009

/Edward D. Pergament/
Edward D. Pergament
(Reg. No. 43,346)